Raymond James downgraded Fusion Pharmaceuticals (FUSN) to Market Perform from Strong Buy with a price target of $21, up from $16. The AstraZeneca (AZN) deal announcement represents another win for the radiopharma space and an invitation to the large and growing collection of radioligand developers to aggressively pursue their programs, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FUSN:
- UK Stocks: AstraZeneca (AZN) Expands Cancer Portfolio with Fusion Pharma Acquisition
- Fusion Pharmaceuticals’ Acquisition and Future Focus Shift
- Fusion Pharmaceuticals downgraded to Market Perform from Outperform at Leerink
- Fusion Pharmaceuticals to be acquired by AstraZeneca in $2.4B transaction
- Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer